注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Uniqure NV是一家位于荷兰的专门从事基因治疗的公司。它寻求为患有遗传性疾病和其他破坏性疾病的患者开发具有潜在治愈效果的一次性治疗方法。它在内部和通过合作伙伴关系开发了一系列基因疗法。它在自己的设施中生产基于腺相关病毒或基于AAV 的基因疗法,具有专有的、商业规模的、当前良好生产规范、合规的制造工艺。AMT-061是该公司针对B型血友病患者的主要候选产品,正在进行一项研究的剂量阶段。AMT-130,亨廷顿舞蹈症患者的候选产品,正在进行I/II期临床研究。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jesús Prieto | - | - | Member of Scientific Advisory Board |
Robin Ali | - | - | Member of Scientific Advisory Board |
Michael R. Hayden | 72 | - | Member of Scientific Advisory Board |
Katherine A. High | 71 | - | Member of Scientific Advisory Board |
Robert Gut | 58 | 2018 | Non-Executive Director |
David D. Meek | 60 | 2018 | Independent Chairman of the Board |
Paula Soteropoulos | 55 | 2013 | Independent Non-Executive Director |
Madhavan Balachandran | 72 | 2017 | Independent Non-Executive Director |
Matthew Craig Kapusta | 51 | 2015 | CEO & Executive Director |
Leonard E. Post | 70 | 2020 | Independent Non-Executive Director |
Jeremy P. Springhorn | 61 | 2017 | Independent Non-Executive Director |
Jack L. Kaye | 79 | 2016 | Independent Non-Executive Director |
Rachelle Suzanne Jacques | 52 | 2021 | Non-Executive Director |
Hugo Katus | - | 2014 | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核